Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nasal spray could offer new hope for Treatment-Resistant depression

NCT ID NCT07716098

Not yet recruiting Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study tests whether esketamine nasal spray, used by itself, can reduce depression symptoms in adults whose depression has not improved with at least two prior antidepressant treatments. Participants are randomly assigned to receive either a low dose (56 mg), a high dose (84 mg), or a placebo spray over four weeks. The main goal is to measure changes in depression severity using a standard rating scale.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
esketamine nasal spray
What this could lead to
If successful, this could offer a fast-acting, standalone treatment option for people with depression that hasn't responded to other antidepressants.
What could go wrong
This is a phase 3 trial, but esketamine may cause side effects like dissociation or dizziness, and not all participants may benefit. Results need to confirm long-term safety and effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSIVE DISORDER, TREATMENT-RESISTANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

depressive disorder Depressive Disorder, Treatment-Resistant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DEPRESSIVE DISORDER, TREATMENT-RESISTANT

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Taipei Medical University

    Taipei, 110, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.